search
Back to results

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Primary Purpose

Chronic Myeloid Leukemia

Status
Active
Phase
Phase 2
Locations
New Zealand
Study Type
Interventional
Intervention
Dasatinib
Imatinib
Sponsored by
University of Auckland, New Zealand
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Myeloid Leukemia focused on measuring Dasatinib, Imatinib

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA:

  1. Male or female patients ≥ 18 years of age.
  2. ECOG performance status score of 0-2.

  3. Patients must have all of the following:

    1. Be enrolled within 3 months of initial diagnosis of CML-CP (date of initial diagnosis is the date of first cytogenetic analysis).

    2. Cytogenetic or molecular confirmation of Ph+ or variants of (9;22) translocations.

      patients may have secondary chromosomal abnormalities in addition to the Ph+.

    3. Documented chronic phase CML as defined by:

      • < 15% blasts in peripheral blood and bone marrow.
      • < 30% blasts plus promyelocytes in peripheral blood and bone marrow.
      • < 20% basophils in peripheral blood.
      • ≥ 100 x 109/L platelets (unless considered related to hydroxyurea).
      • no evidence of extramedullary leukaemic involvement, with the exception of hepatosplenomegaly.
    4. BCR-ABL1 transcript that can be monitored by Q-PCR.
    5. Baseline full blood count (within 14 days of enrolment) remains consistent with chronic phase CML criteria.
  4. Voluntary written informed consent.

EXCLUSION CRITERIA:

  1. Any prior treatment for CML with other than hydroxyurea.

  2. Patients with the following laboratory values:

    1. serum bilirubin > 2.0 x the institutional upper limit of the normal range (ULN).
    2. ALT > 2.0 x the institutional upper limit of the normal range (ULN).
    3. creatinine > 2.0 x the institutional upper limit of the normal range (ULN).
    4. International normalised ratio (INR) or partial thromboplastin time (PTT) > 1.5 x ULN, with the exception of patients on treatment with oral anticoagulants.
  3. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders or infection.

  4. Patients with:

    1. Grade 3/4 cardiac problems as defined by the New York Heart Association Criteria.
    2. Uncontrolled hypertension.
    3. Grade 3/4 respiratory dysfunction.
    4. Past or current history of pleural effusions or pulmonary arterial hypertension.
  5. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required.
  6. Patients who have undergone major surgery within 4 weeks of study Day 0, or who have not recovered from prior major surgery.

  7. Patients who are:

    1. pregnant.
    2. breast feeding.
    3. of childbearing potential without a negative pregnancy test on/prior to Day 0.
    4. male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial (postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential).
  8. Patients with another uncontrolled malignancy with the exception of basal cell skin carcinoma or cervical carcinoma in situ.
  9. Patients with positivity for hepatitis B antigen and / or hepatitis B core antibody (unless receiving prophylactic therapy with lamivudine or more potent agent)
  10. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.

Sites / Locations

  • Auckland City Hospital
  • Middlemore Hospital
  • Christchurch Hospital
  • Dunedin Hospital
  • Waikato Hospital
  • Taranaki Base Hospital
  • Palmerston North Hospital
  • North Shore Hospital
  • Wellington Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Dasatinib

Arm Description

All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2). Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1. Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months.

Outcomes

Primary Outcome Measures

To estimate the proportion of patients who remain in MR3.0 for the duration of 2 years following a change of therapy from dasatinib to imatinib at 13 months.

Secondary Outcome Measures

To estimate progression free survival (PFS), failure free survival (FFS) and overall survival (OS) for patients that switch to imatinib at 13 months.
To estimate the proportion of patients who regain MR3.0 on dasatinib or another TKI therapy after having a confirmed loss of MR3.0 on imatinib, for patients that switch to imatinib at 13 months.
To estimate time to MR3.0, MR4.5 and MR5.0 for patients that switch to imatinib at 13 months.
To describe adverse event profiles on Stage 1 and Stage 2 of the study and overall for patients that switch to imatinib at 13 months.
To describe the quality of life on Stage 1 and Stage 2 of the study and overall for those that switch to imatinib at 13 months.

Full Information

First Posted
June 15, 2017
Last Updated
November 3, 2022
Sponsor
University of Auckland, New Zealand
Collaborators
Leukaemia & Blood Cancer New Zealand
search

1. Study Identification

Unique Protocol Identification Number
NCT03193281
Brief Title
KISS Study: Kinase Inhibition With Sprycel Start up
Acronym
KISS
Official Title
KISS Study: A Phase II Study of Dasatinib Followed by Imatinib in Newly Diagnosed, Previously Untreated Patients With Chronic Phase CML
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 17, 2017 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Auckland, New Zealand
Collaborators
Leukaemia & Blood Cancer New Zealand

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Chronic myeloid leukaemia (CML) is due to a chromosomal abnormality in white blood cells which results in abnormal multiplication. CML in its earlier, slower growing chronic phase (CP) is well controlled by the tyrosine kinase inhibitor (TKI) drug imatinib, which targets the consequences of the chromosomal abnormality, inducing a response and subsequent remission (as measured using molecular techniques on patient blood or bone marrow samples in the lab). Dasatinib, a newer TKI drug, similar in design to imatinib, gives a more rapid molecular response, however the long term side-effects are less known than imatinib. This study will investigate the efficacy and safety of a treatment plan for patients with newly diagnosed CML-CP, where dasatinib will be used to more rapidly induce a molecular response (MR3.0) within 12 months, after which imatinib will be used to maintain the CML in that remission. It is hypothesised that imatinib is safe and effective in maintaining MR3.0 in patients with CML who achieve MR3.0 at 12 months following initial induction therapy with dasatinib.
Detailed Description
The KISS Study is a Phase II, multicentre, open-label, prospective non-randomised study of treatment modification in response to maintenance of MR3.0 at 12 months. Patients must be newly diagnosed with chronic phase CML (CML-CP) (<3 months) and previously untreated with the exception of hydroxyurea. Patients will be recruited from hospital haematology clinics. The majority of patients will have been referred to a haematologist due to suspected CML. Written informed consent will be ensured before any study-specific procedures are undertaken or study data collected, however the majority of assessments carried out for this study are based on standard of care. Patients' eligibility will be determined by the usual procedures carried out for CML diagnosis. Results from both diagnostic procedures and confirmatory screening procedures will constitute baseline data. Once a patient has had their eligibility confirmed and has signed informed consent, they will be enrolled into the trial. The trial consists of two stages: Stage 1: The first 12 months after recruitment (before the possible switch to imatinib). Stage 2: Months 13 - 37. The following measurements/data will be recorded throughout the trial at protocol specified time points: Haematology and biochemistry. PB Q-PCR for BCR-ABL1. Chest x-ray, ECG, ECHO. Medical assessment including physical exam, ECOG performance, weight, vital signs, assessment of extra medullary disease (liver, lymph nodes and spleen), spleen measurement below left costal margin, adverse events and concomitant medications. Haematological and molecular response assessments. Treatment adherence assessment. Patient questionnaire (MDASI-CML). All patients will commence dasatinib (Sprycel®) 100 mg daily. Molecular monitoring of blood BCR-ABL1 transcripts to measure molecular response will occur 3 monthly by Q-PCR as per standard of care procedures. Patients who achieve a BCR-ABL1 level of ≤ 0.1% (MR3.0) by 12 months on treatment will switch treatment to imatinib 400 mg daily if MR3.0 is confirmed at 13 months (and they give their consent to switch). Those patients who do not achieve MR3.0 at 12 months or MR3.0 is not confirmed at 13 months, will remain on dasatinib. Patients with confirmed MR3.0 who choose not to switch to imatinib will continue on dasatinib. Patients that are intolerant of dasatinib in the first 12 months, those that switch to imatinib at 12 months and then lose MR3.0 or those intolerant of imatinib will be treated off study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Myeloid Leukemia
Keywords
Dasatinib, Imatinib

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
A Phase II, multicentre, open-label, prospective non-randomised study of treatment modification in response to maintenance of MR3.0 at 12 months. Molecular response will be measured 3 monthly. Patients who achieve MR3.0 by 12 months, with a confirmed response at 13 months on treatment, will switch treatment to imatinib. Those patients who do not achieve this confirmed response will remain on dasatinib. For patients who achieve confirmed MR3.0 by 13 months we define two study stages. Stage 1 is the first 12 months after recruitment (i.e. before the possible switch to imatinib) and Stage 2 includes the months 13 - 37.
Masking
None (Open Label)
Allocation
N/A
Enrollment
91 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dasatinib
Arm Type
Other
Arm Description
All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2). Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1. Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months.
Intervention Type
Drug
Intervention Name(s)
Dasatinib
Other Intervention Name(s)
Sprycel
Intervention Description
In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1). Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment.
Intervention Type
Drug
Intervention Name(s)
Imatinib
Other Intervention Name(s)
Imatinib-AFT
Intervention Description
Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
Primary Outcome Measure Information:
Title
To estimate the proportion of patients who remain in MR3.0 for the duration of 2 years following a change of therapy from dasatinib to imatinib at 13 months.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
To estimate progression free survival (PFS), failure free survival (FFS) and overall survival (OS) for patients that switch to imatinib at 13 months.
Time Frame
3 years
Title
To estimate the proportion of patients who regain MR3.0 on dasatinib or another TKI therapy after having a confirmed loss of MR3.0 on imatinib, for patients that switch to imatinib at 13 months.
Time Frame
3 years
Title
To estimate time to MR3.0, MR4.5 and MR5.0 for patients that switch to imatinib at 13 months.
Time Frame
3 years
Title
To describe adverse event profiles on Stage 1 and Stage 2 of the study and overall for patients that switch to imatinib at 13 months.
Time Frame
3 years
Title
To describe the quality of life on Stage 1 and Stage 2 of the study and overall for those that switch to imatinib at 13 months.
Time Frame
3 years
Other Pre-specified Outcome Measures:
Title
To estimate PFS, FFS and OS for the following groups: 1) the entire cohort 2) patients not eligible to switch to imatinib at 13 months 3) patients that are eligible but do not switch.
Time Frame
3 years
Title
To estimate time to MR3.0, MR4.5 and MR5.0 for the following groups: 1) the entire cohort 2) patients not eligible to switch to imatinib at 13 months 3) patients that are eligible but do not switch.
Time Frame
3 years
Title
To describe adverse event profiles on each stage of study therapy for the following groups: 1) the entire cohort 2) patients not eligible to switch to imatinib at 13 months 3) patients that are eligible but do not switch.
Time Frame
3 years
Title
To describe the quality of life on each stage of study therapy for the following groups: 1) the entire cohort 2) patients not eligible to switch to imatinib at 13 months 3) patients that are eligible but do not switch.
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Male or female patients ≥ 18 years of age. ECOG performance status score of 0-2. Patients must have all of the following: Be enrolled within 3 months of initial diagnosis of CML-CP (date of initial diagnosis is the date of first cytogenetic analysis). Cytogenetic or molecular confirmation of Ph+ or variants of (9;22) translocations. patients may have secondary chromosomal abnormalities in addition to the Ph+. Documented chronic phase CML as defined by: < 15% blasts in peripheral blood and bone marrow. < 30% blasts plus promyelocytes in peripheral blood and bone marrow. < 20% basophils in peripheral blood. ≥ 100 x 109/L platelets (unless considered related to hydroxyurea). no evidence of extramedullary leukaemic involvement, with the exception of hepatosplenomegaly. BCR-ABL1 transcript that can be monitored by Q-PCR. Baseline full blood count (within 14 days of enrolment) remains consistent with chronic phase CML criteria. Voluntary written informed consent. EXCLUSION CRITERIA: Any prior treatment for CML with other than hydroxyurea. Patients with the following laboratory values: serum bilirubin > 2.0 x the institutional upper limit of the normal range (ULN). ALT > 2.0 x the institutional upper limit of the normal range (ULN). creatinine > 2.0 x the institutional upper limit of the normal range (ULN). International normalised ratio (INR) or partial thromboplastin time (PTT) > 1.5 x ULN, with the exception of patients on treatment with oral anticoagulants. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders or infection. Patients with: Grade 3/4 cardiac problems as defined by the New York Heart Association Criteria. Uncontrolled hypertension. Grade 3/4 respiratory dysfunction. Past or current history of pleural effusions or pulmonary arterial hypertension. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required. Patients who have undergone major surgery within 4 weeks of study Day 0, or who have not recovered from prior major surgery. Patients who are: pregnant. breast feeding. of childbearing potential without a negative pregnancy test on/prior to Day 0. male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial (postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential). Patients with another uncontrolled malignancy with the exception of basal cell skin carcinoma or cervical carcinoma in situ. Patients with positivity for hepatitis B antigen and / or hepatitis B core antibody (unless receiving prophylactic therapy with lamivudine or more potent agent) Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Browett, MBChB
Organizational Affiliation
University of Auckland, New Zealand
Official's Role
Principal Investigator
Facility Information:
Facility Name
Auckland City Hospital
City
Auckland
Country
New Zealand
Facility Name
Middlemore Hospital
City
Auckland
Country
New Zealand
Facility Name
Christchurch Hospital
City
Christchurch
Country
New Zealand
Facility Name
Dunedin Hospital
City
Dunedin
Country
New Zealand
Facility Name
Waikato Hospital
City
Hamilton
ZIP/Postal Code
3204
Country
New Zealand
Facility Name
Taranaki Base Hospital
City
New Plymouth
ZIP/Postal Code
4310
Country
New Zealand
Facility Name
Palmerston North Hospital
City
Palmerston North
Country
New Zealand
Facility Name
North Shore Hospital
City
Takapuna
ZIP/Postal Code
0622
Country
New Zealand
Facility Name
Wellington Hospital
City
Wellington
Country
New Zealand

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

KISS Study: Kinase Inhibition With Sprycel Start up

We'll reach out to this number within 24 hrs